Author: David L. Carpenter, BSN, RN

A practical plan for refill delays and coverage gaps

David L. Carpenter, BSN, RN | Health Content Works

Evidence checked: October 26, 2026.

An empty prescription box can leave you trying to solve several problems at once. The pharmacy may be waiting for stock, your insurer may need more information, or the next fill may cost more than you can afford. Start by finding out exactly what is blocking the prescription and telling your prescriber how much medication you have left.

This guide focuses on the days around a treatment interruption. It covers practical questions to ask and the different missed-dose instructions for Wegovy and Zepbound. It does not provide a personal restart dose or replace the instructions for your prescription. Other GLP-1 products, including Ozempic and Mounjaro, need their own guidance.

Find out what is actually holding up the refill

Ask the pharmacy to describe the problem in plain language. “It is not ready” could mean the prescription has no refills, the strength is unavailable, the insurer considers the refill too early, or prior authorization is incomplete. Each problem has a different person who can resolve it.

Write down the next action and who owns it. If the prescriber needs to send information, ask what information is missing. If stock is the issue, ask whether the pharmacy has an estimated arrival date or can check another location. If the price changed, ask whether the claim was processed through your current insurance and what the pharmacy can tell you about the rejection.

These questions do not guarantee a fill. They make the next phone call more useful. Instead of telling the clinic “the pharmacy will not fill it,” you can explain the precise obstacle and give the pharmacy’s contact details.

A national shortage and a local supply problem are also different. FDA has acknowledged that limited local disruptions can persist after a national shortage is resolved. A pharmacy being out of your strength does not establish a new nationwide shortage or automatically justify a compounded substitute. [1]

Give the prescriber dates and details

Contact the office before your supply runs out when possible. Ask what lead time it needs for renewals and authorizations; there is no single refill schedule that fits every plan or pharmacy. Set a reminder based on the answer, rather than waiting for your last scheduled dose.

Send a short message with the following information:

• The exact product, strength, and formulation you use.
• The date of your last dose and the number of doses remaining.
• The next scheduled dose date and the pharmacy’s stated problem.
• Any recent side effects or difficulty eating or drinking.
• Whether another clinician has changed your medicines or medical care.

For example: “My next Zepbound dose is due Friday. I took my last dose last Friday and have none left. The pharmacy says my prior authorization expired. Please tell me who is handling the renewal and what to do if I cannot obtain the next dose.”

Keep the reply in a place you can find. A written plan should identify the intended product, when to contact the office again, and who will advise you if the delay becomes longer. If you use treatment alongside diabetes medicines, specifically ask whether your glucose monitoring or other treatment needs review during the interruption. Do not independently change insulin or other prescriptions.

A missed dose has product-specific instructions

The following is a summary of current U.S. prescribing information, not a direction to use a recalled, damaged, expired, or otherwise unsuitable supply. Ask a pharmacist about uncertain timing, especially if you are exactly at a cutoff.

Wegovy injection: for one missed dose, the label says to take it as soon as possible if the next scheduled dose is more than 48 hours away. If the next dose is less than 48 hours away, skip it and return to the regular day. After two or more consecutive missed doses, the prescribing information directs restarting dose escalation at a lower dose to reduce gastrointestinal reactions; have your prescriber specify the regimen. [2]

Wegovy tablets: skip a missed dose and take the next dose the following day. Do not apply the weekly injection rule to tablets. [2]

Zepbound: take a missed dose within 96 hours. After that window, skip it and resume on the usual day. Keep at least 72 hours between doses. Its missed-dose section does not supply a universal restart schedule for a prolonged interruption; ask your prescriber for one. [3]

Do not use an internet dose-conversion chart to change brands or formulations. Having an appointment scheduled does not make an improvised dose safe in the meantime.

Make the restart plan before the medicine arrives

A delivery notification tells you the package is coming. It does not answer whether the old regimen is still appropriate after a longer gap. Ask the prescriber to review the time off treatment, prior tolerability, and any changes in your health before you resume.

Get clear answers to these questions: What will I take? On what date? Will there be a new dose-escalation schedule? When should I contact the office about side effects? If a new prescription is needed, has it been sent to the pharmacy that will actually fill it?

If the presentation changes from a pen to a vial or another device, request training for that presentation. Zepbound’s labeling specifically calls for appropriate training when the presentation changes. [3] Even a familiar brand name is not a reason to assume that every package works the same way.

Storage also belongs in that conversation. FDA recommends not using injectable GLP-1 medicine delivered warm or inadequately refrigerated because its quality may be affected. The agency has received complaints about compounded GLP-1 shipments arriving warm or with inadequate ice packs. [4] Do not use that supply or judge its usability by how the liquid looks. Contact the dispensing pharmacy about a replacement. Also report any freezing, time spent outside, or uncertainty about when a container was opened, and ask for product-specific instructions before using a questionable supply.

Keep the daily routine workable during the gap

While the medication issue is being sorted out, choose a few manageable routines you can continue. Put familiar meals on the shopping list. Plan food for a long shift. Keep a place to record questions for the next appointment. These are practical ways to reduce the number of decisions you face; they are not a proven substitute for medication or a promise to prevent weight regain.

If hunger, eating patterns, or weight change, describe what you notice to your care team. Avoid treating each change as evidence that you have failed. The useful question is what support you need while access is uncertain. If tracking weight increases distress, ask the clinician how to monitor progress in a way that works for you.

The STEP 1 extension followed a selected subset of participants for about a year after study treatment and structured lifestyle support ended. People who had taken semaglutide regained a substantial share of the weight they had lost, on average. The extension was exploratory, manufacturer-funded, and studied a much longer withdrawal period than a brief refill delay. It cannot predict what will happen to you after one missed dose or a short gap. [5] For the longer-term evidence, see what happens when treatment stops.

Bring up symptoms separately from weight concerns. Persistent vomiting, inability to keep fluids down, or severe abdominal pain should prompt medical advice rather than waiting for a routine refill reply. Both products warn about serious gastrointestinal problems and dehydration-related kidney injury; their Medication Guides direct stopping treatment and contacting a clinician immediately for severe abdominal pain that does not go away. Seek emergency care for severe or life-threatening symptoms. [2,3]

Avoid turning an access problem into a dosing problem

Tell the office directly if cost is the barrier and what monthly amount you can realistically manage. Ask about a sustainable treatment option and a follow-up plan. This discussion can happen alongside insurance work; you do not have to conceal the financial problem until every appeal is complete.

Do not assume that a friend’s spare supply, a seller in a social group, or a product labeled for research is an appropriate replacement. FDA recommends a prescription filled through a state-licensed pharmacy and warns about unapproved GLP-1 products and unreliable sellers. A quick offer is not a substitute for knowing who prescribed, prepared, and dispensed the medicine. [4]

If a compounded product is being considered for a legitimate medical need, ask the prescriber and pharmacist to explain it. A new vial can have a different concentration. The same syringe marking may therefore deliver a different amount of medicine. FDA has documented compounded semaglutide dosing errors involving confusion between milligrams, milliliters, and units, sometimes requiring hospitalization. Have the pharmacist demonstrate the exact dose rather than calculating a substitute yourself. [6]

Leave the next conversation with a usable plan

Before ending the call, repeat back the next step: who is handling the prescription, when you should expect an update, and whom to contact if that deadline passes. Confirm what to do about the next scheduled dose and whether a longer delay changes the plan.

Keep the pharmacy, prescriber, and insurer messages together so you do not have to reconstruct the story each time. Our insurance-coverage article addresses coverage and cost routes in more detail; this plan is about keeping communication and medication instructions clear while the refill is unresolved. You should not have to guess your way through the gap.

This article provides general education and does not replace advice from your prescriber or pharmacist.

Sources and evidence notes

[1] FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. April 1, 2026 update and earlier shortage discussion. Open source

[2] Novo Nordisk. Wegovy (semaglutide) injection and tablets, U.S. Prescribing Information and Medication Guide, revised June 2026. Sections 2.4, 5.2, 5.5 and 5.6. Open source

[3] Eli Lilly. Zepbound U.S. Prescribing Information, revised August 2026. Sections 2.3, 2.4, 5.2, 5.3 and 5.5; accompanying patient labeling. Open source | Medication Guide

[4] FDA. Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Shipping, pharmacy and patient recommendations. Accessed October 26, 2026. Open source

[5] Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022;24:1553–1564. DOI 10.1111/dom.14725. PMID 35441470. Open source

[6] FDA. Dosing errors associated with compounded injectable semaglutide products. Open source

David L. Carpenter, BSN, RN | Health Content Works

Evidence checked: October 25, 2026.

If you have seen a headline about recalled weight-loss injections, start with the label on your own medication. A specific recall does not establish that every compounded GLP-1 product is affected. It also does not establish that another product is safe simply because its name is absent from that notice.

The Apothecary Pharma recall discussed here involves compounded tirzepatide. Your next step is to have the dispensing pharmacist match your product and lot to the current recall instructions, then coordinate any treatment changes with your prescriber. This article explains that process and why legitimate patient needs for compounding still deserve a careful discussion.

What the FDA record confirms

FDA recall D-0036-2027 identifies Apothecary Pharma LLC of Cary, North Carolina; tirzepatide injection 18 mg/mL in 4 mL multidose vials; and NDC 85091-001-18. The firm initiated the voluntary recall on September 24, 2026. FDA classified it as Class II on October 8, and the report date is October 14. The stated reason is “Lack of Assurance of Sterility.” Distribution is listed as nationwide within the United States. [1]

The record lists lots AP-202622, AP-202623, AP-202624, AP-202625, and AP-202627 through AP-202644. AP-202626 is not listed. FDA lists the recalled quantity as 22 vials. The listed beyond-use dates span October 7 through November 26, 2026. Ask the pharmacist to verify the individual lot and date together rather than relying on the range alone. [1] Several listed beyond-use dates have already passed. Ask the pharmacist what to do with any vial whose beyond-use date has passed.

Those facts describe this recall only. They do not identify Wegovy, Zepbound, Mounjaro, or all compounded semaglutide as recalled products. The retrieved FDA dataset was last updated October 14; later instructions may supersede it. [1]

What a sterility concern means

An injectable medicine needs appropriate controls to prevent contamination. FDA explains that poor compounding practices can produce contaminated medicines or incorrect amounts of an active ingredient, with potentially serious consequences. [2] The reason recorded in this recall does not, by itself, tell us that every vial was tested and found contaminated or that a particular patient has an infection.

Class II describes FDA’s risk classification. It generally involves temporary health effects, with a remote probability of serious consequences. FDA says these recalls are generally conducted at the retail level and patients can generally continue treatment unless the recalling company or FDA directs otherwise. That general explanation is not an individualized clearance to use a particular vial. Follow the instructions that apply to your product and ask your pharmacist about uncertainty. [3]

This distinction matters here. An October 19 NewLife Rx statement posted by Fifty 410 describes the Apothecary recall as retail-level and says patients are not required to stop or return medication. That is a dispensing partner’s account of the compounder’s advice, not an independent FDA determination about your vial. Request the current written notice from your dispensing pharmacy rather than relying on a social post or this article alone. [4]

Check the vial before making assumptions

Take a clear photo of the label and keep the outer packaging, receipt, and any recall message. Record the actual compounding pharmacy as well as the telehealth company or clinic that arranged the prescription. Those may be different businesses. FDA specifically notes that people buying through telehealth services may not know who made the medicine. [2]

Have these details ready for the pharmacist:

• The complete medication name, including any added ingredients.
• The concentration in mg/mL and the vial size.
• The lot number and beyond-use date.
• The pharmacy name, prescription number, and dispensing date.
• The date you first punctured the vial, if applicable.
• Your last dose date and when the next dose is due.

Do not post a photo showing your prescription number, address, or other personal details in a public group. Send it through the pharmacy’s usual secure channel. If the lot is missing or unreadable, ask the pharmacy to check its dispensing records. A mismatched or incomplete label deserves clarification, not a guess.

Ask for a specific plan

You can use this message: “I received compounded tirzepatide from your pharmacy. Please check my product and lot against recall D-0036-2027 and any other applicable recall. Is my dispensed medication affected, and what are the current written instructions for patients?”

Then ask whether the instruction is to continue, hold, return, or replace it, and who will coordinate with your prescriber. If your next dose is due before you can obtain an answer, use the pharmacy’s urgent contact or your prescriber’s on-call service. This article cannot determine whether your particular dose should be taken.

If the applicable notice says not to use the product, follow that direction. Keep it separate from medication you are using, and ask about return or disposal instructions before throwing away the packaging. Record the name of the person you spoke with and the date. FDA advises following recall-specific instructions; return and refund arrangements depend on the company or retailer. [3]

If you already used an affected lot, tell the clinician when you injected it and describe any symptoms. Contact a clinician promptly about fever or chills, or redness, warmth, swelling, pain, or drainage at an injection site, especially if worsening or spreading. These can be signs of infection and need assessment. [9] Confusion, shortness of breath, extreme pain, or rapidly worsening illness with possible infection warrants emergency assessment; call 911 for severe or life-threatening symptoms. CDC identifies sepsis as a life-threatening medical emergency. A recall notice alone does not diagnose infection or sepsis. [5]

Why patients need a fair conversation about compounding

People looking for compounded treatment may be facing an unaffordable prescription, lost insurance coverage, or a genuine problem with an ingredient. Those circumstances deserve respect. A patient should be able to explain the problem without being dismissed or pressured into buying something else.

Compounding has legitimate medical uses. FDA gives examples such as removing a dye that causes an allergy or making a liquid for someone who cannot swallow a tablet. But a compounded medicine is not an FDA-approved generic: FDA does not review that finished product for safety, effectiveness, and quality before marketing. Whether a specific compounded GLP-1 is medically appropriate requires a patient-specific discussion. [2]

Affordability and regulatory eligibility are separate questions. FDA’s April 1, 2026 update describes restrictions on routine copies of commercially available drugs. For certain patient-specific changes under section 503A, the prescriber must determine and document a significant difference for the identified patient. Adding vitamin B12 does not automatically avoid the copy restrictions. Section 503B outsourcing facilities follow different conditions. [6]

In that April 1, 2026 update, FDA stated that semaglutide and tirzepatide were not on the relevant 503B bulks list or FDA’s shortage list. A local difficulty filling a prescription does not, on its own, establish that a product qualifies for shortage-based compounding. Ask the prescriber and pharmacist to explain the clinical need and applicable requirements instead of treating a lower advertised price as the answer. [6]

A replacement needs its own instructions

If a pharmacy supplies a different formulation, do not carry over the old syringe measurement from memory. FDA has documented dosing errors involving compounded semaglutide, including confusion among milligrams, milliliters, and syringe units. Ask the pharmacist to confirm the prescribed dose, concentration, correct syringe, and exact measurement for the new product. [7]

Also ask about storage and the discard date after opening. FDA recommends not using injectable GLP-1 medicine that arrives warm or with insufficient refrigeration. For doses drawn from a vial, use a new, sterile needle and syringe each time. For compounded GLP-1 medicines in multidose vials, FDA advises discarding the vial within 28 days after first use, even if medicine remains or the compounder allows longer. Approved branded presentations have their own labeling. An unopened beyond-use date is not permission to keep using an opened vial indefinitely. [8]

FDA recommends obtaining a prescription and using a state-licensed pharmacy. Be cautious when a seller describes a compounded product as identical to an approved drug, cannot identify the pharmacy, or supplies unclear instructions. [8] Ask questions before paying for a replacement you may not be able to use.

Keep one written record of the recall check and the treatment plan. The goal is a clear decision about your own medication, without turning a narrow recall into either a blanket reassurance or a reason to abandon care.

If replacing a recalled product leaves a gap in treatment, see our guide to handling refill delays. If cost or coverage is also a barrier, our guide to insurance denials and affordability questions can help you prepare the next call.

This article provides general education and does not replace advice from your prescriber or pharmacist.

Sources and evidence notes

[1] FDA openFDA drug enforcement record D-0036-2027. Dataset updated October 14, 2026. Exact product, dates, lots, quantity, classification and reason. Open source

[2] FDA. Compounding and the FDA Questions and Answers. Medical need, approval status, risks and pharmacy identity. Open source

[3] FDA. Understanding Drug Recalls What to Know and What to Do. Class II and patient instructions. Open source

[4] Fifty 410. Apothecary Pharma Recall Update. NewLife Rx statement published October 19, 2026, 8:44 PM CDT. Commercial dispensing-partner statement, not an FDA directive. Open source

[5] CDC. About Sepsis. Updated August 17, 2026. Signs and urgency. Open source

[6] FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. April 1, 2026 update and earlier shortage discussion. Open source

[7] FDA. Dosing errors associated with compounded injectable semaglutide products. Used for dosing-error evidence only; its older product-availability descriptions are not a current formulation list. Open source

[8] FDA. Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Multidose-vial guidance and patient recommendations. Open source

[9] MedlinePlus (National Library of Medicine). Cellulitis. Reviewed April 1, 2025. General skin-infection signs and when to contact a clinician; not evidence that this recall caused infection. Open source

Photo by Mediamodifier / Unsplash. Illustrative stock photograph; no endorsement or medication use is implied.

By David L. Carpenter, BSN, RN
Evidence checked: November 1, 2026 (Medicare GLP-1 Bridge update); other evidence last checked October 22, 2026 | United States

A refill that suddenly costs more than you can afford can turn an ordinary pharmacy trip into a difficult decision. You may be wondering whether to appeal, switch medicines, pay out of pocket, or stop treatment. The most useful first step is to find out exactly what changed while asking your prescriber to help you plan for any gap.

This guide focuses on adults using Wegovy or Zepbound who face an insurance or affordability problem. It offers questions to ask and a way to organize the next steps. Your plan documents determine coverage; your prescriber and pharmacist should guide medication changes. A denial does not, by itself, tell you whether continuing treatment is medically appropriate.

Find out what the pharmacy rejection means

Ask the pharmacist for the exact rejection message. Then contact the insurer or pharmacy benefit manager using the number on your insurance card. Ask whether the problem is a missing or expired prior authorization, a formulary change, a benefit exclusion, a pharmacy restriction, or your share of the cost. A formulary is the plan’s list of covered medicines. Review the plan’s written coverage materials rather than relying only on the price at the register. [1]

If the answer is “not covered,” ask the representative to be more specific. Does the plan exclude this drug, exclude treatment for this purpose, or need more clinical information? Ask for the relevant policy and the effective date of any change. These questions help your clinician decide what to submit; they do not guarantee an exception.

Keep one record with the date, representative’s name, call reference number, and promised next step. Save the denial letter and pharmacy messages. Note the date of your last dose and how much medicine remains, so you and your prescriber can plan around your next due dose.

Ask about an exception or appeal

HealthCare.gov’s guidance describes Marketplace coverage, including drug exceptions and possible temporary access during review. Employer plans, especially self-funded plans, Medicare, and Medicaid may follow different rules. Ask which process applies to your plan and whether a transition refill is available. Your prescriber may need to explain why covered alternatives are unsuitable. [1,9]

For a denial under your insurance plan, rather than the Medicare Bridge described below, read the instructions for an internal appeal. An independent external review may also be available, depending on the plan and the type of denial. Follow the deadline in your notice. If a delay could seriously threaten your health, ask your clinician whether an expedited review is appropriate. An appeal challenges a decision; it does not promise that an excluded benefit will become covered. [2]

Make the request specific: “What information is missing, who needs to submit it, and where should it go?” Ask your clinician’s office who handles authorizations and whether they received the denial. You can also ask your employer’s benefits office to help identify the correct contact. Avoid sending the same incomplete request repeatedly without understanding why it failed.

Compare costs you can sustain

Manufacturer copay cards and self-pay offers are different programs. Commercial-insurance cards generally exclude government-program enrollees; self-pay offers have separate terms. Eligibility may depend on insurance, dose, formulation, and refill timing. Some plans do not count copay-card money toward your deductible. If yours does this, the card terms may bar you from using it; other plan arrangements can also affect eligibility. Read the exact program’s current terms; offers may change. [3,4,10]

Ask for the price of your actual prescription after any introductory offer ends. Paying cash does not automatically count toward your deductible or out-of-pocket limit. Some offers prohibit seeking reimbursement or submitting payments toward those limits. Confirm this before paying, and include any visits, membership fees, supplies, or shipping in your comparison. [4,10]

Bring a realistic spending limit to your prescriber. A useful question is: “If I cannot afford this medicine next month, what treatment options are appropriate for me?” The alternative may involve a different approved medicine or a revised care plan. Do not treat different drugs, doses, or delivery devices as interchangeable. Coverage and clinical suitability both need checking.

If you have Medicare

Since July 1, 2026, the temporary Medicare GLP-1 Bridge has offered eligible people with qualifying Medicare drug coverage certain weight-management medicines for $50 a month. These include Foundayo tablets, Wegovy injections and tablets, and Zepbound KwikPen, but not Zepbound vials or single-dose pens. The Bridge is scheduled to end December 31, 2027. See the current CMS program information and Medicare.gov covered-drug list (checked November 1, 2026). The payments do not count toward your Part D deductible or annual out-of-pocket limit. [12,13]

Your plan type and health criteria matter, and your prescriber must request approval. The Bridge operates outside the usual Part D benefit. It has no appeals process, but your prescriber can resubmit corrected or additional information. If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH (a type of fatty liver disease) with moderate-to-advanced liver scarring, or your medicine is prescribed to reduce major cardiovascular events, the Bridge does not apply. Your coverage request must go through your Part D plan instead; approval is not guaranteed, and a denial follows the Part D appeal process. A Bridge denial is different from a Part D plan denial. Call 1-800-MEDICARE (1-800-633-4227) to clarify which route applies. [12,13]

Plan a treatment gap before changing doses

Send your prescriber the medication name, formulation, current dose, last dose date, remaining supply, and expected length of the gap. Ask for written instructions covering what to do now and how to restart. Avoid independently stretching the interval between injections or improvising smaller doses to make a supply last.

For weekly Wegovy injection, the current U.S. label directs restarting dose escalation at a lower dosage after two or more consecutive missed doses to reduce gastrointestinal side effects. Its Medication Guide tells patients who miss two or more consecutive weeks to contact their prescriber about restarting. Have your prescriber select the dose. [5]

Wegovy tablets are taken daily: skip a missed tablet and take the next dose the following day, without an extra dose. Tablets and injections are not interchangeable milligram for milligram. Tablets also have separate fasting and timing instructions; ask your pharmacist to review them if your formulation changes. [5]

For one missed weekly Zepbound dose, the label allows taking it within four days, or 96 hours. After that, skip it and take the next scheduled dose. Keep at least three days, or 72 hours, between doses. This is not a universal restart schedule after several missed doses; ask your prescriber before resuming. [6]

If you have diabetes, ask about glucose monitoring and other medicines during the gap and restart, particularly insulin or sulfonylureas. Do not adjust them independently. Seek prompt medical care for persistent severe abdominal pain, repeated vomiting, or inability to keep fluids down. [5,6]

If you use oral hormonal contraception, Zepbound’s label calls for a non-oral method or added barrier protection for four weeks after starting and after each dose increase. Ask how this applies if restarting involves dose escalation. [6]

Understand what stopping research can and cannot tell you

In the STEP 1 extension, the group previously assigned semaglutide 2.4 mg regained, on average, about two-thirds of its earlier weight loss during the following year. The exploratory analysis included 327 selected trial completers across treatment groups; structured lifestyle support also stopped. Selection could affect the findings. Novo Nordisk funded the trial, and authors disclosed industry relationships, including manufacturer employment. This was not a study of a brief insurance gap. [7]

That result supports planning for ongoing care, but it cannot predict your weight change over a week or a month. It also does not establish what a specific person taking tirzepatide will experience. Regain should prompt a treatment discussion, not a conclusion that you failed.

Keep daily routines manageable

During the disruption, choose a few routines you can realistically maintain. For example, write down a simple grocery list, plan regular meals around your work schedule, and keep activity at a level that fits your health and abilities. If your care team has given you nutrition or fluid restrictions, continue to follow them.

These are practical ways to organize a difficult week, not a proven substitute for medication or a guarantee against regain. If hunger becomes harder to manage, report it to your care team. Agree on a follow-up date and decide together whether weight, symptoms, blood glucose, or other measures would be useful to track.

Be careful with cheaper online substitutes

FDA warns that unapproved GLP-1 products do not undergo its review for safety, effectiveness, and quality. Compounded products are not FDA-approved generics of Wegovy or Zepbound. FDA has received reports of dosing errors with compounded injectable semaglutide, including cases requiring hospitalization. [8]

Use a licensed prescriber and a state-licensed pharmacy, but remember that licensure does not make a compounded product FDA-approved. Avoid products sold as research chemicals or “not for human consumption.” If compounding is proposed, ask why an approved medicine cannot meet your medical needs and request clear product and dosing instructions. [8]

FDA reports that the national semaglutide and tirzepatide injection shortages are resolved. Its April 1, 2026 update explains restrictions on compounding products that are essentially copies of available approved drugs. The rules depend on the compounding circumstances; do not assume shortage-era availability still applies. Ask the prescriber and pharmacist to explain the current basis for the proposed product. [11]

A practical next call

You can tell your clinician’s office: “My next refill has been rejected or is unaffordable. My last dose was on [date], my dose is [dose], and I have [supply] left. Can you help identify the coverage problem and give me a plan if I miss treatment?”

Before ending the call, clarify who will contact the insurer, when you should expect an update, and whom to call if the next dose is due before the issue is resolved. You do not need to solve every insurance question before asking for clinical help.

A coverage interruption can require a change in treatment, but it does not have to mean losing contact with care. Work on access and the medical plan together, with costs you can sustain and restart instructions you understand.

Sources

1. HealthCare.gov. Getting prescription medications.
https://www.healthcare.gov/using-marketplace-coverage/prescription-medications/

2. HealthCare.gov. How to appeal an insurance company decision.
https://www.healthcare.gov/appeal-insurance-company-decision/appeals/

3. Novo Nordisk. Wegovy cost and coverage information and linked program terms.
https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html

4. Eli Lilly. Zepbound savings and insurance options and program terms.
https://zepbound.lilly.com/savings

5. Novo Nordisk. Wegovy U.S. prescribing information and Medication Guide. Revised June 2026. Sections 2.4, 2.5 and 5; accessed October 22, 2026.
https://www.novo-pi.com/wegovy.pdf

6. Eli Lilly. Zepbound U.S. prescribing information and Medication Guide. Revised August 2026. Sections 2.3, 5, 7.2 and 8.3; accessed October 22, 2026.
https://pi.lilly.com/us/zepbound-uspi.pdf

7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–1564. doi:10.1111/dom.14725.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/

8. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

9. U.S. Department of Labor. Filing a claim for your health benefits.
https://www.dol.gov/agencies/ebsa/about-ebsa/our-activities/resource-center/publications/filing-a-claim-for-your-health-benefits

10. Novo Nordisk. Wegovy savings offer eligibility and terms.
https://www.novocare.com/eligibility/wegovy-savings-card.html

11. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. April 1, 2026 update.
https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

12. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: Information for Providers. Updated August 6, 2026; accessed October 22, 2026.
https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers

13. Medicare.gov. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month. Product No. 12234, June 2026; accessed October 22, 2026.
https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf

Related reading

• What Happens When You Stop Wegovy or Zepbound?
• When Hunger or Food Noise Returns on Wegovy or Zepbound

Photo by Rajasekhar R on Unsplash. Stock photograph for illustration.

By David L. Carpenter, BSN, RN | Health Content Works

You start a medication to help manage your weight. You expect your appetite to change. Our guide to changes in hunger and food noise explains how to describe a different kind of craving. Then you notice something you were not expecting: you do not seem as interested in having a drink.

That raises a reasonable question. Is the medication doing something, or is something else going on? And if it is affecting alcohol cravings, could it help someone whose drinking has become a problem?

Researchers are asking those questions, too. Human studies of semaglutide are encouraging, including trials published in 2026. But the details matter. A change in the desire to drink, a reduction in heavy drinking, and successful treatment of alcohol use disorder are different outcomes. We should be clear about which one a study actually measured.

First, a safety issue that cannot wait

If you drink heavily and regularly, do not assume that losing interest in alcohol makes it safe to stop abruptly on your own. Withdrawal can be life-threatening. Contact a healthcare professional before making a major change so they can assess your risk and arrange appropriate care. Do not devise your own withdrawal plan. A weight-management medication is not a substitute for withdrawal care. [1,2]

Shaking, sweating, nausea, or a racing heart after cutting back can be signs of withdrawal. Contact a healthcare professional right away or go to an emergency department if you suspect withdrawal. Seizures, hallucinations, severe confusion, fever, or an irregular heartbeat in this setting require emergency care: call 911 in the United States. Do not dismiss these as routine medication side effects. [2]

If low energy is another concern, our guide to fatigue during treatment can help you organize what to discuss with your clinician. It does not replace the urgent withdrawal guidance above.

Wegovy and Zepbound are different medications

Wegovy contains semaglutide. Zepbound contains tirzepatide. Current U.S. labeling for these products does not include alcohol use disorder as an indication. That matters when a headline starts sounding like a treatment recommendation. The trials below tested particular oral or injectable semaglutide regimens, not every product containing the drug. [3,4]

It also matters when the headline says “weight-loss drugs,” but the study tested only semaglutide. Evidence about one medication does not establish the same effect for another. If you take Zepbound, the semaglutide findings are interesting, but they cannot tell you what your own response will be.

A 2024 study of electronic health records associated semaglutide use with fewer newly recorded or recurrent alcohol use disorder diagnoses than comparator medications. Statistical matching made the groups more comparable, but could not remove every difference in who received treatment or how diagnoses were recorded. This was observational evidence, not proof that semaglutide prevented or treated the disorder. [5]

What the semaglutide studies found

A 2025 randomized trial followed 48 adults with alcohol use disorder who were not seeking treatment. Its primary question concerned drinking during a laboratory session. Semaglutide reduced the amount consumed and peak breath alcohol concentration, although only 25 participants had complete data for that analysis. The registered secondary measure of average drinks per calendar day did not significantly improve. Exploratory measures of weekly craving and drinks per drinking day improved; the number of drinking days did not. The nine-week trial used low injectable doses and could not establish lasting recovery. [6]

Those distinctions can sound fussy until you think about what they mean. Drinking less on an evening when you drink is different from drinking on fewer evenings. Both may matter to someone trying to change, but they are not interchangeable.

A 2026 trial at one center randomized 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and obesity. Both groups received cognitive behavioral therapy alongside either weekly semaglutide injections or placebo for 26 weeks. The primary outcome was change in heavy-drinking days. The estimated reduction was 13.7 percentage points greater with semaglutide than placebo (95% confidence interval, 5.4 to 22.0 points). Eighty-eight participants completed treatment; the analysis included all 108 using statistical estimates for missing outcomes. Gastrointestinal side effects were more common with semaglutide. These findings concern medication alongside counseling in a specific population, not a universal benefit or proof of lasting effects after stopping. [7]

An eight-week 2026 trial at one U.S. center randomized 50 adults seeking treatment for moderate-to-severe alcohol use disorder to oral semaglutide or placebo. Its primary endpoint—craving after alcohol cues in a laboratory at week six—did not differ significantly between groups. Of two key secondary drinking measures during the final four weeks, heavy-drinking days favored semaglutide, but average drinks per calendar day did not. Exploratory measures, including everyday craving, also favored semaglutide. The researchers did not adjust for testing multiple outcomes, increasing the possibility of chance findings. [8]

The trial was small and brief. All participants had overweight or obesity, most were White, and drinking was self-reported. Some placebo participants may have recognized their assignment, which could affect results. These limits matter when considering how the findings might apply to other people. [8]

Taken together, these findings give researchers a reason to keep going. They also give us a reason to resist turning a promising result into a guarantee. The studies differed in participants, formulation, treatment setting, and follow-up. We cannot simply combine their best results and call that what everyone should expect.

Where does that leave Zepbound?

A 2026 case report described three people with obesity, type 2 diabetes, and alcohol-associated liver disease whose self-reported alcohol intake fell after starting tirzepatide. Only one had documented alcohol use disorder, and that person had previously received another medication to reduce drinking. There was no comparison group, and other health changes occurred alongside treatment. The report cannot establish that tirzepatide caused the reduction or predict benefit for people taking Zepbound. [9]

So, if your interest in alcohol changes while taking Zepbound, tell your prescriber. It is useful information. It is not a reason to raise the dose yourself, switch medications, or assume you now have treatment for an alcohol problem. The semaglutide results do not answer those questions for tirzepatide.

Less craving is worth noticing. It is not the whole picture.

Craving is the urge to drink. Drinks per drinking day describes quantity on days someone drinks; drinking days describes frequency. Heavy-drinking days counts days that meet a study’s specified intake threshold. These measures answer different questions. Improvement in one does not, by itself, establish remission from alcohol use disorder. The diagnosis involves a broader assessment of impaired control and alcohol-related problems. [1,6,7,8]

You do not need to turn your life into a research project. If you notice a change, jot down what changed and when. Was it the urge to drink? The amount you drank? How often you drank? Did the change happen around a medication start or dose change? Were you also feeling sick? Bring those observations to your appointment rather than trying to prove the medication was responsible.

Be equally honest if nothing changed. You have not failed a test because someone online lost interest in alcohol and you did not. A study describes what happened in a group. It cannot promise what will happen to you.

What to discuss with your prescriber

A straightforward way to start is: “Since starting this medication, my interest in alcohol has changed. Can we talk about what that means for me?” If drinking has been difficult to control, say that directly, too. You do not need a polished explanation.

Tell your clinician how much and how often you drink, what medications you take, and what treatment you already receive. Be clear about any previous withdrawal, especially seizures or severe confusion. Ask whether you need a separate alcohol assessment and what support fits your situation. Research on semaglutide does not replace established alcohol care. Do not stop an existing alcohol treatment because a weight-management medication seems to be helping.

Evidence-based alcohol care already exists. Depending on the person, it can include medications, behavioral treatment, or a combination. Care can begin with a primary care clinician or an addiction specialist; it does not always mean residential treatment. NIAAA’s Alcohol Treatment Navigator explains treatment options and how to look for qualified help. [10]

Keep medication side effects in the conversation as well. The Wegovy and Zepbound guides advise stopping the medication and contacting a healthcare professional right away for severe abdominal pain that does not go away, with or without vomiting; the pain may extend to the back. Persistent vomiting or diarrhea also deserves a call because dehydration can cause kidney problems. Do not explain away significant symptoms as evidence that the medication is “working.” [3,4]

There is room for hope and careful questions

It is reasonable to be interested in this research. It is also reasonable to want better answers before making treatment decisions. We need to know who benefits, how durable the effects are, and how these medications fit with established alcohol care.

For now, notice changes, describe them honestly, and bring them to the clinician who knows your health history. If alcohol is causing problems, you deserve help now. You do not have to wait for the next study to ask for it.

General educational information, not individualized medical advice. Prepared with AI assistance and reviewed by David L. Carpenter, BSN, RN.

Sources and further reading

Evidence checked: October 17, 2026. The Lancet trial was reviewed at abstract level. Access to some full texts was limited; verification of the oral semaglutide trial and tirzepatide case report included indexed passages from the original papers.

1. NIAAA. Treatment for Alcohol Problems: Finding and Getting Help.

2. MedlinePlus. Alcohol withdrawal. Reviewed January 1, 2025.

3. DailyMed. Wegovy medication guide.

4. DailyMed. Zepbound medication guide.

5. Wang W, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. 2024;15:4548. doi:10.1038/s41467-024-48780-6.

Correction to reference 5. Published June 18, 2024. doi:10.1038/s41467-024-49655-6.

6. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82:395–405. doi:10.1001/jamapsychiatry.2024.4789.

7. Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10540):1687–1698. doi:10.1016/S0140-6736(26)00305-3. Abstract accessed.

8. Schacht JP, et al. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. American Journal of Psychiatry. 2026;183(9):636–645. doi:10.1176/appi.ajp.20260003.

9. Takizawa H, et al. Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity. Endocrinology, Diabetes & Metabolism Case Reports. 2026;2026(2):EDM260002. doi:10.1530/EDM-26-0002.

10. NIAAA Alcohol Treatment Navigator. Types of Alcohol Treatment.

Photo by Anna Pelzer / Unsplash. Illustrative stock photograph; no endorsement or medication use is implied.

Understanding the change and deciding what to discuss

By David L. Carpenter, BSN, RN | Health Content Works

Evidence checked: October 17, 2026.

For a while, food took up less room in your day. You could finish a meal and move on. Now you are thinking about your next snack again, and a familiar worry follows: Is the medication still working?

That question deserves a useful answer. But first, it helps to describe what has actually changed. Wanting lunch, craving a particular food, and being unable to concentrate because thoughts about eating keep interrupting you are different experiences. They can also happen together.

This article is for adults using Wegovy or Zepbound injections. Its purpose is to help you explain returning hunger or intrusive food thoughts without turning them into a diagnosis, a personal failure, or a reason to change your prescription yourself.

Start with what you mean by hungry

You do not need the perfect medical term. Try describing the experience in ordinary language:

• “I feel ready for a meal sooner than I used to.”
• “I keep wanting one particular food, even after dinner.”
• “Thoughts about eating keep interrupting work, and it is hard to focus.”
• “Once I start eating, I sometimes feel unable to stop.”

Those examples describe experiences, not diagnoses or a screening test. Physical hunger, a craving, repeated food thoughts, and feeling unable to control eating can overlap, but they are not the same. Feeling unable to control eating deserves its own discussion.

People often use “food noise” to describe persistent, intrusive thoughts about food. Researchers are studying the concept, but its boundaries and clinical meaning remain debated. A 2026 scholarly commentary highlights overlap with cravings and food preoccupation, and cautions that measurement tools still have limits. It is a discussion of the evidence, not a treatment trial. [1]

For our purposes, the useful question is how the experience affects your day. Looking forward to dinner is different from repeatedly losing your place in a conversation because you cannot stop thinking about food. A label should help you explain that difference, not make every food thought feel like a problem.

What the research can tell us

A randomized, placebo-controlled study tested weekly semaglutide injections in 72 adults with obesity for 20 weeks. At week 20, participants receiving semaglutide reported less hunger, better control of eating, and fewer or weaker cravings than those receiving placebo. The dose was gradually increased to 2.4 mg. [2]

This was a small, single-center study that excluded people with diabetes-range blood test results. Appetite ratings were secondary outcomes; the eating-control questionnaire was exploratory. Novo Nordisk funded the study, and several authors were company employees. [2]

These findings concern appetite during a small, 20-week study. The trial did not test returning food thoughts months later or determine how to adjust treatment when appetite changes. It did not study tirzepatide, the medicine in Zepbound, so its findings should not be applied to both products. [2]

Stopping treatment is a separate question. In the STEP 1 extension, a subset of 327 participants was followed after semaglutide and structured lifestyle support ended at week 68. Over the following year, those previously receiving semaglutide regained, on average, about two-thirds of their prior weight loss. This was an observational follow-up, not a new randomized comparison of stopping versus continuing. [8]

In SURMOUNT-4, participants who completed 36 weeks of tirzepatide were randomized to continue it or switch to placebo for 52 weeks. Those switched to placebo regained weight on average; those continuing lost more. Lifestyle counseling continued in both groups. [9] These studies concern weight maintenance. They do not establish why hunger returns during continued treatment, an individual food-noise timeline, or a dose-adjustment plan. [8,9]

Returning hunger is information to assess

“The medicine stopped working” is a conclusion. “I am hungry again before dinner” is an observation. Starting with the observation leaves room to investigate instead of deciding the answer before the appointment.

Medication benefit is broader than how little you want to eat. NIDDK describes treatment decisions in terms of benefits, side effects, other health conditions and medicines, and cost. Continuing treatment can be appropriate when it helps a person maintain a health improvement. [3] Your prescriber can assess those factors alongside the appetite change.

A change in hunger also is not the same thing as a weight-loss plateau. One describes an experience; the other describes a weight pattern over time. If the scale has stalled too, bring up both concerns. HCW’s separate plateau article addresses that question without making this another guide to weighing and tracking.

Look at the circumstances around the change

Before reaching for a new rule, consider a few ordinary details. Are you getting through the workday on very little food? Has nausea made meals difficult? Are you sleeping differently, working longer hours, or taking a new medicine? These are details to discuss, not proof of why your appetite changed.

If you notice the change near the end of the injection week, describe when it happens. Timing alone does not tell you that the dose is wrong. It also does not justify shortening the interval between injections. Both Medication Guides say to use the medicine as your healthcare provider directs. Ask your prescriber or pharmacist about concerns. [4,5]

Mention any missed doses, supply interruption, storage concern, or uncertainty about using the device. A pharmacist can review the instructions for the exact product you have. There is no single missed-dose or restart rule that applies to both medicines. [4,5]

The practical aim is to find the part of the plan that needs attention. If you cannot eat comfortably, that deserves help. If your schedule leaves no reasonable meal break, tell your care team what a typical shift looks like. More restriction is not automatically the answer to either problem. For practical eating guidance, see Low appetite and small meals.

Do not turn eating into a test of treatment

You do not have to prove that treatment works by seeing how long you can avoid food. NIDDK notes that, for some people, skipping meals or not eating enough may contribute to binge eating. That does not explain everyone’s hunger, but it is a reason to avoid responding to distress with increasingly restrictive rules. [6]

If food thoughts are upsetting or you feel out of control while eating, say so directly. Eating unusually large amounts in a short period, feeling unable to stop, eating secretly because of embarrassment, and distress afterward are concerns worth discussing. A clinician can assess whether an eating disorder is present; hunger or a craving alone does not establish one. [6]

A registered dietitian or a clinician experienced in eating concerns may help assess what support fits. Our goal here is a useful conversation, not a plan to suppress every appetite signal or a promise that a particular snack, supplement, or higher dose will solve the problem.

An example of a more useful conversation

Consider Jordan, a fictional reader. Jordan says, “The medicine is wearing off.” Asked to explain, Jordan describes eating very little during work and then spending the evening thinking about food.

A clearer starting point might be: “For the past two weeks, I have been thinking about food through most of the evening. My work meals have been small because I feel full quickly. I have not changed my dose. Can we review whether I am eating enough, what the medication is doing, and whether I need additional support?”

That example does not diagnose Jordan’s situation. It gives the clinician something concrete to explore. Your own description might be completely different. You can explain what happens, how often it happens, and what it keeps you from doing without collecting a month of records first.

When symptoms need prompt attention

Do not dismiss sudden hunger with shaking, sweating, dizziness, or confusion as food noise. These can be signs of low blood sugar. [4,5] Wegovy’s guide highlights risk in people with type 2 diabetes, especially with insulin or a sulfonylurea. Zepbound’s guide warns that risk may be higher with medicines such as insulin or a sulfonylurea. If you have a glucose-checking and treatment plan, follow it. Seek urgent help if you cannot safely treat yourself or symptoms are severe. Loss of consciousness or a seizure requires emergency help. [7] Hunger alone does not diagnose hypoglycemia. [4,5,7]

Both Medication Guides instruct you to stop the medicine and contact your provider right away for severe abdominal pain that persists, sometimes extending to the back, with or without nausea or vomiting. This is the warning for possible pancreatitis. They also say to contact your provider promptly if nausea, vomiting, or diarrhea does not go away, because dehydration can lead to kidney problems. Severe symptoms or an inability to keep fluids down warrant urgent medical advice. [4,5]

These safety instructions are separate from ordinary questions about appetite. Do not raise doses, add injections, or take a medication break to experiment with hunger. Use your prescribed instructions and ask for a treatment review. [4,5]

Leave with a question you can act on

Ask your clinician: “Does this sound like ordinary hunger, an intake problem, troublesome food preoccupation, or something else? How will we assess whether treatment is still helping? What should we do next, and when should I check back?”

You do not need to wait for weight regain before discussing a change that is troubling you. The point is to understand what is happening and agree on an appropriate next step. Feeling hungry is something you can talk about openly. It is not a character flaw.

General educational information, not individualized medical advice. Prepared with AI assistance and reviewed by David L. Carpenter, BSN, RN.

Sources

Focused review, not a systematic review. Source 1 was assessed from its indexed abstract.

[1] Brewis A, et al. Food noise: Conceptual, methodological, and ethical considerations. Appetite. 2026;226:108700. Published online July 2, 2026. doi:10.1016/j.appet.2026.108700. Commentary; abstract accessed.

https://pubmed.ncbi.nlm.nih.gov/42392316/

[2] Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021;23:754–762. doi:10.1111/dom.14280. Publisher full text accessed.

https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.14280

[3] NIDDK. Prescription Medications to Treat Overweight and Obesity. General treatment principles; not a product-specific dosing protocol.

https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

[4] Novo Nordisk. Wegovy Medication Guide. DailyMed, combined injection and tablet record. This article applies the injection instructions only. Guide revised June 2026; accessed October 17, 2026.

https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

[5] Eli Lilly. Zepbound Medication Guide. DailyMed. Guide revised August 2026; accessed October 17, 2026.

https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

[6] NIDDK. Symptoms and Causes of Binge Eating Disorder. Last reviewed May 2021. General eating-disorder guidance, not GLP-1-specific evidence.

https://www.niddk.nih.gov/health-information/weight-management/binge-eating-disorder/symptoms-causes

[7] NIDDK. Low Blood Glucose Hypoglycemia. Last reviewed July 2021. General diabetes guidance.

https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia

[8] Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022;24(8):1553–1564. doi:10.1111/dom.14725.

https://doi.org/10.1111/dom.14725

[9] Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331:38–48.

https://doi.org/10.1001/jama.2023.24945

Related HCW reading

Weight loss plateaus

Low appetite and small meals

Fatigue during treatment

Photo by Holly Stratton / Unsplash. Illustrative stock photograph.

Evidence checked: October 14, 2026. Prepared with AI assistance and reviewed and approved for publication by David L. Carpenter, BSN, RN.

You hoped treatment would help you feel better. Instead, you are reaching the end of a workday with less energy than you expected. Perhaps the stairs feel harder, you keep wanting a nap, or cooking dinner suddenly seems like too much effort.

Those changes deserve attention. Fatigue appears in the prescribing information for both Wegovy and Zepbound, but that does not establish why you personally feel tired. [1,2] The useful question is not simply, “Is this a side effect?” It is, “What has changed, how is it affecting me, and what needs to be checked?”

This article concerns adults using Wegovy or Zepbound injections. It offers a way to organize that conversation, rather than a medication adjustment or a treatment plan for fatigue.

When tiredness should not wait

Call for emergency help. Call 911 or your local emergency number for loss of consciousness, new confusion, or trouble breathing. [9] A seizure or inability to safely treat severe low blood sugar also needs immediate help. [4] Do not wait to finish a symptom record.

Get medical help right away if dehydration comes with no urine, a racing heartbeat, fast breathing, confusion, or fainting. Earlier signs can include dark urine, less urination, thirst, and dizziness. [5] Both Medication Guides say to contact your provider right away for nausea, vomiting, or diarrhea that persists, because fluid loss can harm the kidneys. [1,2] HCW also advises prompt contact if you cannot keep liquids down.

Stop the medicine and call your provider right away for severe, persistent abdominal pain, which may spread to your back, whether or not you also have nausea or vomiting. Both Medication Guides give this instruction for possible pancreatitis, or inflammation of the pancreas. [1,2] If you are severely ill, seek emergency care.

For fatigue without urgent warning signs, discuss treatment changes with your prescriber rather than stopping, skipping, or changing doses on your own. [3] This does not override instructions in your Medication Guide or an existing care plan.

Mental-health crises need prompt support too. If you are thinking about suicide or harming yourself, contact the U.S. 988 Suicide & Crisis Lifeline by phone or text. Call 911 for immediate danger. This is general crisis guidance, not a claim that GLP-1 medicines cause these thoughts. [9,10]

What the medication evidence tells us

In three weight-reduction trials lasting up to 68 weeks, 11% of adults receiving Wegovy 2.4-mg weekly injections reported fatigue, compared with 5% receiving placebo. The groups included 2,116 and 1,261 participants, respectively. Participants had obesity or overweight. The label combined fatigue and asthenia, meaning weakness, in this category. These figures apply to this dose and trial population, not every Wegovy formulation or dose. [1]

Zepbound’s figures come from two pooled weight-reduction trials lasting up to 72 weeks. Adults had obesity or overweight, with or without type 2 diabetes. Fatigue was reported by 5% in the 5-mg group (630 participants), 6% in the 10-mg group (948), and 7% in the 15-mg group (941). The placebo figure was 3% among 958 participants. The category combined fatigue, weakness, lethargy, and malaise. These are study groups, not dosing advice. [2]

Both labels caution against directly comparing side-effect rates across different drugs’ trials. [1,2] These percentages cannot tell us which medicine is less tiring. They also cannot explain an individual’s fatigue, predict when it will resolve, or establish a remedy.

A claim such as “this always passes after a few weeks” goes beyond what these figures show. So does assuming that a low number on the scale makes declining energy acceptable.

Describe the feeling before trying to fix it

“Tired” can mean several different things. MedlinePlus distinguishes fatigue, or low energy, from drowsiness, which is the urge to sleep. [3] In conversation, be more specific if you can:

• “I am struggling to keep my eyes open.”
• “I am awake, but ordinary tasks feel exhausting.”
• “My legs feel weaker when I get up from a chair.”
• “I become lightheaded when I stand.”

These descriptions give your clinician a clearer starting point than a single tiredness score. Mention when the problem began, whether it is constant or comes in episodes, and whether it followed a prescribed treatment change.

Timing is useful evidence to bring, not proof of a cause. If you notice a pattern around injection day, record it without experimenting with your dose or moving injections around to test a theory.

Look at eating and drinking without blaming yourself

Has reduced appetite changed what you can actually manage? Maybe lunch has become a few bites, nausea interrupts dinner, or a busy shift leaves little opportunity to drink. Tell your care team about these obstacles instead of presenting only a weight measurement.

General fatigue guidance includes nutrition among the factors worth reviewing. [3] That does not mean every tired person on a GLP-1 has a deficiency or needs a supplement. A clinician or registered dietitian can help assess whether intake is adequate for your circumstances.

If you can eat and drink comfortably and have no warning signs, keep familiar, tolerated food and fluids accessible. Avoid turning a difficult week into another restrictive diet experiment. Keep following any fluid limit your clinician has prescribed.

For practical food options, see HCW’s Low Appetite on Wegovy or Zepbound article. Here, the useful question is whether eating or drinking has become difficult and needs assessment.

Keep blood sugar in context

Low blood sugar can cause low energy, shaking, sweating, dizziness, weakness, or confusion. [1,2,4] Combining Wegovy or Zepbound with insulin or a sulfonylurea can increase this risk. [1,2] Skipping or delaying meals can also matter when taking medicines that lower blood sugar. [4]

If you have a glucose-monitoring and low-blood-sugar plan, follow it when symptoms occur. Seek urgent help for severe symptoms or if you cannot safely treat yourself. Ask the clinician managing your diabetes about recurrent episodes; do not independently adjust insulin or other prescribed medicines.

Fatigue alone does not diagnose hypoglycemia. Nor does this article mean that everyone needs to buy a continuous glucose monitor. The right assessment depends on your medicines, symptoms, and medical history.

Sleep and other medicines still matter

New tiredness does not erase problems that existed before treatment. Loud snoring, witnessed breathing pauses, gasping during sleep, and daytime sleepiness can be clues to sleep apnea. Discuss them rather than assuming weight loss has already corrected your sleep. [6]

Keep using prescribed CPAP or other sleep-apnea treatment unless your treating clinician changes it. NHLBI recommends follow-up and says a large weight change may warrant another sleep study. A reassessment, rather than symptoms alone, helps guide treatment decisions. [7]

Bring a complete medicine list, including nonprescription sleep aids and allergy products. Some medicines can contribute to fatigue or drowsiness. Other possible causes include anemia, thyroid disorders, depression, and infection. [3] These are reasons for an individualized assessment, not a list of conditions you should assume you have.

Protect your opportunity to sleep. If you are too sleepy or fatigued to drive or operate equipment safely, stop and arrange a safer option. [7] As a practical precaution, do not treat caffeine as proof that you are safe to continue.

Make one useful note, not a new project

NIH appointment guidance supports preparing your main concerns and an up-to-date medication list. [8] A short description of the problem is enough to begin; you do not need a detailed tracking system.

A brief note might include:

• When the change started and any prescribed medication changes around that time.
• What “tired” means for you, plus any accompanying symptoms.
• One ordinary task that has become harder.
• Whether eating, drinking, sleep, or other medicines have changed.
• Readings you already collect under your care plan, if relevant.

This is an optional communication tool, not a validated GLP-1 fatigue test. A few observations are enough to start a conversation. Never delay care while collecting them.

For example, fictional reader Morgan writes: “Since last week, I have needed to sit down halfway through grocery shopping. I am awake, but feel drained. I have been allowing eight hours for sleep. Can we review the symptoms and my medicines, and decide whether I need an examination or testing?”

Morgan’s note explains the change, its practical effect, and the question that needs answering. If symptoms are urgent, use your local urgent or emergency-care route rather than waiting for a routine portal reply.

Ask for a plan that includes follow-up

Arrange an appointment for unexplained fatigue, particularly if it comes with fever, unintended weight loss, or recurring sweats. Your clinician can review your symptoms, history, and medicines and decide whether an examination or tests are needed. [3] As a practical starting point, explain whether your energy is getting worse or limiting ordinary activities.

Useful questions include: “Which possible causes fit my situation? Could any of my medicines be contributing? Do I need an examination, tests, or nutrition or sleep support? When should I check back, and what should prompt an earlier call?”

Agree on how you will tell whether the plan is helping. That might mean managing your usual activities more comfortably, rather than adding another daily measurement. HCW’s Progress Beyond the Scale article offers broader context for discussing function alongside weight.

You do not have to prove that the medicine caused your fatigue before asking for help. A treatment plan should account for how you are functioning as well as what the scale says.

General educational information, not individualized medical advice. Prepared with AI assistance and reviewed and approved for publication by David L. Carpenter, BSN, RN.

Sources

Evidence checked: October 14, 2026. This is a focused educational review, not a systematic review.

[1] Novo Nordisk. Wegovy prescribing information and Medication Guide. DailyMed record updated June 18, 2026; injection-specific trial data, section 6.1, Table 3. Combined record also covers tablets and other injection dosing; these are not the source of the quoted 11% versus 5% figures.

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

[2] Eli Lilly. Zepbound prescribing information and Medication Guide. Revised August 2026. Section 6.1, Table 1; Medication Guide safety instructions.

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

[3] MedlinePlus Medical Encyclopedia. Fatigue. General symptom evaluation; not GLP-1-specific treatment evidence.

https://medlineplus.gov/ency/article/003088.htm

[4] NIDDK. Low Blood Glucose (Hypoglycemia). General diabetes guidance.

https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia

[5] MedlinePlus. Dehydration. Warning signs and assessment.

https://medlineplus.gov/dehydration.html

[6] NHLBI. Sleep Apnea: Symptoms.

https://www.nhlbi.nih.gov/health/sleep-apnea/symptoms

[7] NHLBI. Sleep Apnea: Living With. Follow-up and reassessment after weight change.

https://www.nhlbi.nih.gov/health/sleep-apnea/living-with

[8] NIH Health. How To Prepare for a Doctor’s Appointment. General communication guidance.

https://health.nih.gov/health-topics-a-z/prepare-for-appointment

[9] MedlinePlus Medical Encyclopedia. Recognizing medical emergencies. General emergency guidance.

https://medlineplus.gov/ency/article/001927.htm

[10] 988 Suicide & Crisis Lifeline. U.S. crisis support. https://988lifeline.org

Photo: Aaron Burden / Unsplash.

Evidence reviewed October 9, 2026. Prepared with AI assistance and reviewed and approved for publication by David L. Carpenter, BSN, RN.

A plan you can discuss with your clinician

You may know the weight you hope to reach without knowing what to focus on this week. A distant number does not tell you which question to bring to an appointment, what to do when a plan feels unmanageable, or whether the next priority should be nutrition, movement, symptoms, or access to care.

For adults using Wegovy or Zepbound injections, this article helps you choose a priority and prepare a next question or action. Medical targets belong in a discussion of your preferences, treatment response, side effects, other health conditions, and practical constraints.

This article offers a way to prepare that conversation. It draws on general public-health and communication guidance, with medication safety grounded in the product Medication Guides. The planning framework and fictional examples are editorial tools, not a tested GLP-1 program or a prediction of weight loss.

Separate the outcome from the next action

An outcome is something you hope will change: your weight, a health measurement, or your ability to enjoy an activity. An action is something you plan to do: arrange a follow-up, practice an agreed exercise, or ask for help with a meal plan. They can belong together without being interchangeable.

The CDC encourages specific, realistic short-term goals and regular reassessment. [1]

For example, “I want to feel more comfortable joining family outings” describes a personal priority. “At my next appointment, I will ask what activity is appropriate for my starting point and knee symptoms” describes a concrete next step.

A person can complete an agreed action without getting the hoped-for result. That is information for the next conversation, not proof of personal failure. Equally, checking off actions does not establish that medication is effective or safe. Treatment assessment remains a clinical decision.

Choose a priority before adding more rules

Imagine writing down everything you think you should improve and then asking: which item most needs attention now? The answer may be a medical concern rather than a lifestyle task. Difficulty eating, troublesome symptoms, or a likely interruption in access deserves a conversation rather than another personal challenge.

For ordinary planning, try completing this sentence: “I would like help with ___ because it is affecting ___.” It might be uncertainty about suitable movement, conflicting nutrition advice, or not understanding what the clinician wants reviewed at follow-up.

You do not need to adopt someone else’s goal because their starting weight, medication, or online story sounds similar. Bring your own priorities and constraints. A goal that assumes gym access, predictable breaks, or money for extra appointments may need a different approach in your life.

NIH guidance recommends listing concerns in order of importance and raising the most important ones early in the visit. It also encourages telling the clinician how treatment and changes in your life are affecting you. [2]

Make the plan clear enough to discuss

A short goal statement can identify an action, the situation in which it will happen, and when you will revisit it. You can also include the question that must be answered before acting. For example: “Before choosing an exercise class, I will ask whether my balance difficulties require an assessment or an adapted option.”

That question makes the uncertainty visible. A useful plan can begin with getting information rather than immediately increasing effort.

If your clinician has already given you a plan, ask which part deserves attention first. You can say, “I understand the overall recommendation, but I cannot manage all these changes at once. Which one should I prioritize?” Avoid interpreting a general online goal as permission to override an individualized plan.

NIDDK’s habit-change guidance supports starting with small changes, anticipating obstacles, and revisiting goals. [3]

Agree on what would make the plan worth continuing

Before trying an ordinary routine change, decide what question you want it to answer. “Was this manageable?” is different from “Did I lose weight?” The first can help you describe whether a plan fits your circumstances. The second needs interpretation alongside the wider treatment picture.

For example, arranging an appointment may resolve confusion about nutrition but reveal a need for dietitian support. Learning an adapted movement may make a plan clearer even before any change in weight.

If a health measurement matters to the question, ask your clinician what, if anything, should be measured and when. A review date is a chance to reassess; it is not a promise that a particular amount of weight will be lost by then.

Keep any personal notes proportionate to the question. A sentence about what you tried and what got in the way may be enough for a practical discussion. Do not add repeated weighing, food calculations, or measurements simply to make the record look complete. If your clinical team requires specific monitoring, follow that plan.

For measurement guidance, see HCW’s progress article. If slowing weight loss is your concern, the plateau article addresses that separate question:

Progress Beyond the Scale on Wegovy or Zepbound

Weight-Loss Plateau on Wegovy or Zepbound

Discuss barriers without turning them into blame

A plan can fail to fit even when you understand it. An unpredictable schedule, food costs, fatigue, mobility limitations, caregiving, transportation, or difficulty contacting the clinic can change what is feasible. Name the obstacle directly instead of translating it into “I need to be better.”

If the difficulty is access to treatment, tell the prescriber or pharmacist before improvising. Ask who can help and what to do if the problem continues. Do not stretch doses, borrow medicine, change the schedule, or restart after an interruption using a lifestyle worksheet.

NIDDK explains that setbacks are common and do not mean failure. It suggests reviewing your plan and asking friends or family for help. That general advice should not be used to dismiss symptoms or imply that a person can solve every barrier by trying harder. [3]

You might decide to simplify an ordinary task, ask for an accessible alternative, or request clarification. Changing a routine and changing prescribed treatment are different decisions. Use the medicine as directed and take medication questions to the prescriber or pharmacist. [4,5]

A fictional example of choosing a different first goal

Consider Morgan, a fictional reader using one of these medicines, who arrives with the goal “lose as much as possible before a family trip.” Morgan is also unsure whether an old exercise plan still fits a painful knee and has been collecting conflicting food advice online.

An initial conversation could instead begin: “I want to participate comfortably in the trip. Can we agree on an appropriate activity plan and clarify the nutrition advice I should follow?” Morgan can ask which concern should come first and what would warrant another appointment.

The next action might be arranging the recommended assessment or bringing the conflicting advice to a dietitian. Its purpose is to show how a vague demand can become a question that a care team can actually address.

Leave with an agreed next step

Before the visit ends, confirm what you will do, what the care team will do, and how to get clarification. NIH encourages asking questions, taking notes, and learning the office’s preferred communication method. Nurses and pharmacists can also be useful sources of information. [6]

A brief note could read: “My priority is ___. The next step we agreed on is ___. I need help with ___. If a review is appropriate, we will revisit it ___. I should contact ___ sooner if ___.” Use only the parts of this optional conversation aid that help you.

MedlinePlus suggests asking for written instructions or an interpreter and bringing a support person when helpful. Its appointment guidance applies to in-person and telehealth visits. [7] A practical suggestion: if hearing, vision, travel, or technology makes appointments difficult, tell the office what you need and ask what options are available. Do not fill in missing medication directions with assumptions.

Symptoms take priority over goal setting

Do not wait for a planned goal review if you develop concerning symptoms. Both Medication Guides instruct patients to stop using the medicine and contact their healthcare professional right away for severe abdominal pain that does not go away, with or without nausea or vomiting; the pain may extend to the back. This pancreatitis warning is a specific safety instruction, not routine permission to change doses. [4,5]

Both guides also warn about dehydration and kidney problems associated with nausea, vomiting, or diarrhea and advise contacting the healthcare provider right away if those symptoms do not go away. They also advise telling the provider about stomach problems that are severe or do not go away. [4,5] For a medical emergency, call 911 or your local emergency number rather than waiting for a routine message. [8]

You do not need to solve the entire treatment journey today. A worthwhile starting point is a priority you can explain, an appropriate next action, and an agreed way to reassess. The purpose is clearer care and a manageable plan—not a test of willpower.

General educational information only; not individualized medical advice.

Sources

Evidence checked October 9, 2026. These are official guidance and labeling sources, not trials of this article’s planning framework.

1. CDC. Steps for Losing Weight. January 17, 2025. Steps 3 and 5: realistic goals and reassessment. Accessed October 9, 2026.

https://www.cdc.gov/healthy-weight-growth/losing-weight/index.html

2. NIH Health. How To Prepare for a Doctor’s Appointment. Priorities, life changes, and medicines.

https://health.nih.gov/health-topics-a-z/prepare-for-appointment

3. NIDDK. Changing Your Habits for Better Health. Last reviewed November 2020.

https://www.niddk.nih.gov/health-information/diet-nutrition/changing-habits-better-health

4. Novo Nordisk. Wegovy (semaglutide) Medication Guide. Revised June 2026; PDF pages 19–20. The guide covers injections and tablets; this article applies only the safety instructions relevant to injections. Accessed October 9, 2026.

https://www.novo-pi.com/wegovy.pdf

Wegovy Medication Guide on DailyMed

5. Eli Lilly. Zepbound (tirzepatide) injection, for subcutaneous use. Medication Guide, revised August 2026; side effects, PDF pages 2–3. Accessed October 9, 2026.

https://pi.lilly.com/us/zepbound-us-mg.pdf

Zepbound Medication Guide on DailyMed

6. NIH. Talking With Your Doctor or Health Care Provider. Last reviewed March 4, 2025.

https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/clear-communication/talking-your-doctor-or-health-care-provider

7. MedlinePlus. Talking With Your Doctor. Updated October 5, 2024; accessed October 9, 2026. Written instructions, interpreters, support people, and telehealth.

https://medlineplus.gov/talkingwithyourdoctor.html

8. MedlinePlus Medical Encyclopedia. Recognizing medical emergencies. Reviewed January 8, 2025; accessed October 9, 2026.

https://medlineplus.gov/ency/article/001927.htm

Related HCW reading

Progress beyond the scale

Weight loss plateaus

Making a routine work during a busy week

Photo: Brooke Lark / Unsplash. Illustrative food image; not a prescribed meal or constipation treatment.

Evidence checked: October 9, 2026. Prepared with AI assistance and reviewed and approved for publication by David L. Carpenter, BSN, RN.

A change in bathroom habits can be an uncomfortable part of weight-management treatment. You may be eating smaller meals, adjusting to a new routine, and wondering whether harder stools are something to tolerate or something to report.

Constipation is listed among the common side effects of both Wegovy and Zepbound. That makes it a reasonable topic to bring up with your prescriber, not an embarrassing complaint you need to minimize. Common does not mean every episode is harmless. [1,2]

This guide is for adults using Wegovy or Zepbound injections. It explains how to describe the problem, when to seek help, and which everyday changes or treatment questions may be worth discussing. It does not provide a personalized laxative regimen or medication-dose plan.

Check for warning signs first

Get medical assessment right away if constipation occurs with constant abdominal pain, vomiting, inability to pass gas, fever, rectal bleeding, or blood in the stool. Severe or worsening pain, especially with vomiting, marked abdominal swelling, or inability to pass gas or stool, warrants emergency care because a bowel blockage is possible. Do not wait for every symptom to appear. [3,9]

If a blockage is possible, do not start or increase fiber supplements, laxatives, enemas, or other constipation remedies while delaying assessment. Sudden constipation with cramps and inability to pass gas or stool is specifically a reason to avoid laxatives and call for medical help immediately. [8,10]

Persistent severe abdominal pain, sometimes reaching the back, with or without nausea or vomiting, can signal pancreatitis. Both Medication Guides instruct patients with that pattern to stop using the medicine and contact their healthcare professional immediately. This is a specific emergency warning, not a suggestion to adjust routine doses yourself. [1,2]

Both guides warn that ongoing nausea, vomiting, or diarrhea can cause dehydration and kidney problems; contact your prescriber right away if these symptoms persist. Seek prompt assessment if you cannot keep fluids down or are urinating much less. Fainting, confusion, or no urination warrants emergency assessment. [1,2,11]

Describe more than how often you go

Constipation can involve fewer than three bowel movements a week, but frequency is only part of the picture. Hard or lumpy stools, difficult or painful passage, and feeling that you have not emptied completely also matter. Report a meaningful change from your usual pattern rather than relying on a single number. [3]

For example, “I went yesterday” leaves out whether passing stool required painful straining. “I have not gone as often” leaves out whether the stool remains comfortable to pass. Those details help your clinician understand the problem without requiring you to diagnose its cause.

A short description can start the conversation: when the change began, what passing stool feels like, and whether pain, vomiting, bleeding, or trouble passing gas is present. You do not need a perfect diary before asking for help.

What the medication evidence tells us

A published post-hoc analysis pooled three 68-week trials involving adults with overweight or obesity. During the on-treatment analysis, constipation rates adjusted for differences among the trials were 24.2% in the semaglutide 2.4 mg group and 11.1% in the placebo group. The pooled groups included 2,117 and 1,262 participants, respectively. One trial included people with type 2 diabetes; the other two did not. [4]

Novo Nordisk funded the trials and medical writing support for this paper; several authors were company employees. This was a post-hoc safety analysis. It combined trials with different populations and lifestyle interventions and relied on reported adverse events; it did not test constipation treatments. Its results do not predict your individual experience or estimate tirzepatide risk. Zepbound’s own Medication Guide identifies constipation as a common adverse effect. [2,4]

Avoid assuming that every bowel change has only one cause. Changes in food intake, fluids, activity, daily routine, other medicines, or an underlying condition can contribute. Iron supplements and some pain medicines, for example, can worsen constipation. Review the whole picture with your care team. [3]

Build food and fluid changes gradually

For mild symptoms without warning signs, general constipation guidance supports gradually adding suitable fiber-containing foods and drinking enough fluid. NIDDK lists foods such as oats and other whole grains, beans, lentils, fruits, and vegetables. Introduce fiber gradually so your digestive system can adjust. Fluid needs vary with health, activity, body size, and other circumstances. [5]

A practical starting question is whether your smaller meals still include any of those foods. If they have largely disappeared, ask a dietitian how to include a tolerable amount while meeting the rest of your nutrition needs. This does not require turning every meal into a large salad.

For example, you might discuss keeping a familiar fruit with breakfast or adding a small amount of lentils to a meal you already tolerate. Choose foods you tolerate; these examples are not a tested constipation treatment.

If your clinician has restricted fluids or given you a specific dietary plan, check before changing it. Do not force a universal water target or a large increase in fiber. If an attempted change makes symptoms worse, describe that response to your clinician rather than assuming you need to keep increasing it.

Give your bowel routine a little room

NIDDK says regular physical activity may help relieve constipation. Its guidance also encourages allowing time for a bowel movement rather than ignoring the urge. Trying the bathroom at a consistent time can help establish a routine; after breakfast is one suggested opportunity because eating stimulates colon activity. A footstool may make the position more comfortable. These are general constipation measures, not a proven GLP-1-specific program. [6]

Choose an opportunity that fits your life. For a shift worker, that may mean protecting a little time after the first meal of the waking day. A person with mobility limitations may need a different setup or assistance. The aim is a workable routine, not a requirement to produce a bowel movement on demand.

Activity should match your abilities and existing care plan. A brief comfortable walk may be a practical option for some people. It is not a reason to exercise through abdominal pain or postpone assessment of a concerning symptom.

Ask about remedies rather than stacking products

If everyday measures are not helping, ask your clinician or pharmacist what is appropriate. Laxatives and fiber supplements are not interchangeable, and the right choice depends on your symptoms, medical history, and other medicines.

The 2023 AGA–ACG guideline strongly recommends polyethylene glycol, or PEG, for adults with chronic idiopathic constipation. “Idiopathic” means there is no identified underlying cause. This guidance is useful background, but it is not direct evidence from trials treating constipation caused by Wegovy or Zepbound. [7]

The guideline conditionally supports fiber supplements; psyllium has the best evidence among the fibers evaluated, although certainty is low. Supplements require adequate fluid, and gas can occur. It also warns against magnesium oxide in people with impaired kidney function because magnesium can accumulate. A supplement being sold without a prescription does not make it suitable for everyone. [7]

PEG helps retain water in stool. MedlinePlus advises following directions and discussing possible bowel obstruction, medicines, and supplements with a healthcare professional before use. Bloating, cramps, or nausea can occur. [8] Follow the warning-sign guidance above: seek assessment for vomiting or significant abdominal pain rather than increasing laxative doses to work around those symptoms. [3,10]

Bring the actual product names or photographs of their labels to the discussion. Ask which product to use, how long to try it, what side effects to watch for, and when to call if it fails. A clear plan is more useful than adding a powder, gummy, tea, and tablet without knowing which ingredient is doing what.

Make the follow-up conversation useful

If symptoms persist, recur, or do not improve with self-care, arrange a clinical review. Review other medicines and possible underlying causes rather than repeatedly adding OTC products. Ongoing difficulty despite appropriate treatment may require pelvic-floor assessment or tests of bowel function. Your clinician decides which evaluation is appropriate. Do not change routine prescribed treatment on your own; the pancreatitis warning above is a separate safety instruction. [6,12]

Keep a brief note while arranging follow-up: the date of your last bowel movement, stool hardness, straining or incomplete emptying, associated symptoms, and anything you tried. Include when symptoms began relative to starting treatment or a prescribed dose change. Include other medicines and supplements, such as iron or opioid pain medicines. Keep the record brief. [3]

A message might read: “Since my recent treatment change, stools have become hard and difficult to pass. My last bowel movement was __. I have tried __. I do/do not have abdominal pain, vomiting, bleeding, or difficulty passing gas. What should I do next?” If warning signs are present, seek prompt care instead of relying on a routine portal message.

Constipation deserves attention even when weight loss is going well. The goal is comfortable bowel function and a treatment plan you can tolerate. Report the problem early, use routine measures thoughtfully, and get individualized help when those measures are not enough.

General educational information only; not individualized medical advice.

Sources

All sources accessed October 9, 2026. The Wegovy PDF includes injection and tablet labeling; this article addresses injections only.

1. Novo Nordisk. Wegovy Prescribing Information and Medication Guide. Revised June 2026. Medication Guide: possible side effects (PDF pages 19–20); injection scope.

https://www.novo-pi.com/wegovy.pdf

2. Eli Lilly. Zepbound Medication Guide. Revised August 2026. Possible side effects (PDF pages 2–3).

https://pi.lilly.com/us/zepbound-us-mg.pdf

3. NIDDK. Symptoms & Causes of Constipation. Last reviewed May 2018.

https://www.niddk.nih.gov/health-information/digestive-diseases/constipation/symptoms-causes

4. Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24:94–105. DOI: 10.1111/dom.14551.

https://doi.org/10.1111/dom.14551

5. NIDDK. Eating, Diet, & Nutrition for Constipation.

https://www.niddk.nih.gov/health-information/digestive-diseases/constipation/eating-diet-nutrition

6. NIDDK. Treatment for Constipation.

https://www.niddk.nih.gov/health-information/digestive-diseases/constipation/treatment

7. Chang L, et al. AGA–ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Gastroenterology. 2023;164:1086–1106. DOI: 10.1053/j.gastro.2023.03.214.

https://doi.org/10.1053/j.gastro.2023.03.214

8. MedlinePlus. Polyethylene Glycol 3350. Drug information.

https://medlineplus.gov/druginfo/meds/a603032.html

9. MedlinePlus / NIDDK. Intestinal Obstruction.

https://medlineplus.gov/intestinalobstruction.html

10. MedlinePlus Medical Encyclopedia. Fecal impaction. Warning against laxatives with sudden constipation, cramps, and inability to pass gas or stool.

https://medlineplus.gov/ency/article/000230.htm

11. MedlinePlus. Dehydration. Warning signs and urgent assessment.

https://medlineplus.gov/dehydration.html

12. American Gastroenterological Association GI Patient Center. Constipation: Refractory. Secondary causes and testing.

https://patient.gastro.org/constipation-refractory/

Related HCW reading

Meal planning for GLP-1 users

Low appetite and small meals

Building a routine around work

Photo: S’well / Unsplash. Illustrative meal-preparation image; not a prescribed meal plan.

Evidence checked October 8, 2026. Prepared with AI assistance and reviewed and approved for publication by David L. Carpenter, BSN, RN.

A long shift, a delayed lunch break, and a pile of laundry can make even a sensible health plan difficult to follow. You may know what you intended to eat or when you hoped to walk. The harder question is how to make that happen when your day changes halfway through.

For adults using Wegovy or Zepbound injections, a workable routine starts with the schedule you actually have. This article helps you identify one recurring barrier and try one practical adjustment around work and home responsibilities. It does not prescribe a diet, change medication instructions, or promise better weight loss.

The planning examples below are editorial suggestions, not a tested GLP-1 treatment program. Medication safety comes from current product labeling; sleep, activity, and food-safety guidance comes from the official sources identified below.

Look at the difficult parts of your week

Before buying containers or downloading another app, look at your next few workdays. When do you leave home? Where can you safely store food? How predictable are your breaks? When can you contact the pharmacy while it is open? Include your commute and sleep rather than counting only paid work hours.

Choose the problem that repeatedly gets in your way. Perhaps food is available but requires a microwave you cannot reach. Perhaps your day off disappears into errands, leaving nothing prepared for the next morning. Those problems need different solutions.

Write one sentence about the obstacle and one possible adjustment. “My lunch needs reheating, so I will bring something that can be eaten cold” is a concrete experiment. “I need more discipline” does not tell you what to change. If breaks are consistently unavailable, discuss coverage or workplace arrangements with your supervisor or occupational-health service.

Prepare for the break you may actually get

Use the nutrition plan you already have as the starting point. Pick familiar foods that you tolerate and can manage with the storage and equipment available. If you need help deciding what or how much to eat, bring those questions to your clinician or registered dietitian. HCW’s meal-planning article provides a separate starting point for that discussion.

Consider packing components separately so an interrupted break does not mean unpacking an entire meal. For example, someone might bring a sandwich and fruit, while another person needs different foods because of allergies, symptoms, or their individual plan. Adapt those choices to your own nutrition plan.

Choose one backup you would genuinely use: an appropriate shelf-stable item, a familiar option at work, or an easy meal available at home. A backup does not need to be a special “GLP-1” product. Check its storage instructions and suitability for your needs.

Food safety still applies when the shift gets busy. FDA guidance limits time at room temperature for foods needing refrigeration to two hours, or one hour when the air temperature is above 90°F. Keep cold foods at 40°F or below, whether in a refrigerator or a cooler with enough ice or frozen gel packs to maintain that temperature. An insulated bag alone does not guarantee safe storage. Food can be unsafe without smelling spoiled. Plan reliable cold storage before packing leftovers or dairy for a long shift. ^{[1], [6]}

Make access to fluids part of the plan

Think through where drinks are allowed and when you can reach them. A bottle in your bag is not useful if your bag stays somewhere inaccessible all day. Arrange a practical place to keep it, consistent with workplace rules.

If your care team has given you fluid instructions, build around those rather than adopting an online gallon challenge. This article does not set a universal fluid target.

Both Medication Guides warn that nausea, vomiting, or diarrhea can cause dehydration and kidney problems. Contact your prescriber right away if these symptoms do not go away. If you cannot keep fluids down, seek prompt medical assessment rather than waiting for the shift to end. ^{[2], [3]}

Protect time for sleep

For night workers, “after work” may be morning. NIOSH guidance for nurses working night shifts advises protecting daytime sleep, keeping the bedroom dark, reducing noise, and asking others not to interrupt. This is general shift-work guidance, not evidence that a particular sleep schedule improves semaglutide or tirzepatide results. ^[4]

One practical application is deciding which chores can wait until after waking. Another is telling household members when you will be unavailable. If elaborate meal preparation keeps pushing sleep later, simplify the preparation task instead of assuming every meal must be cooked from scratch.

A routine also needs room for caregiving and shared living space. Aim for changes you can actually arrange. Discuss persistent difficulty sleeping or staying alert with a healthcare professional.

Fit movement into the week without making every day identical

An exercise plan can look different on a workday and a day off. CDC guidance allows weekly aerobic activity to be spread into smaller amounts and recommends choosing activities that match your abilities. These are general activity principles, not proof that brief walking breaks prevent medication-associated muscle loss. ^[5]

Look for realistic opportunities within the activity plan appropriate for you. A familiar short walk might fit one day; a planned strength session might fit another. Avoid treating a physically demanding shift as a reason to push through pain or exhaustion after work.

For strength-training ideas and the distinction between walking and resistance exercise, use HCW’s beginner guide. This article’s purpose is to help you find a place for that plan in your week, rather than add another workout program.

Keep medication logistics separate from lifestyle experiments

Keep a reminder for the prescribed schedule and a record of doses actually taken. Check refill arrangements before your supply runs out. If cost, stock, or scheduling causes an interruption, contact the pharmacy or prescriber.

Missed-dose instructions differ between Wegovy and Zepbound. Use the instructions for your exact product and ask your pharmacist when unsure; do not improvise catch-up doses. This article concerns injections, not oral semaglutide. ^{[2], [3]}

If medication must travel with you, have your pharmacist explain the storage instructions for that specific pen or vial. Do not assume different presentations have interchangeable storage limits. ^{[2], [3]}

A changed work schedule is a reason to review the logistics with your prescriber or pharmacist if symptoms, missed doses, or interruptions affect your plan. It is not an instruction to change treatment yourself.

Know which symptoms should interrupt the routine

Severe abdominal pain that persists, sometimes extending to the back, with or without nausea or vomiting, can signal pancreatitis. Both Medication Guides instruct patients with this pattern to stop the medicine and contact their healthcare professional immediately. Seek urgent assessment. This is a specific safety instruction, not advice to make routine dose changes yourself. ^{[2], [3]}

If you also take insulin or a sulfonylurea, ask the clinician managing your diabetes how to handle delayed meals and recognize and treat low blood sugar. Both labels warn of greater hypoglycemia risk with these medicines. Follow your established plan rather than adjusting doses yourself. ^{[2], [3]}

These examples do not cover every medication warning. Read the full Medication Guide and seek help for concerning symptoms rather than waiting until your next day off.

Try one change over the next few workdays

Consider two fictional examples. A night worker prepares a simple work bag after waking and asks family to protect the post-shift sleep period. A daytime worker checks the lunch refrigerator on arrival and keeps a suitable backup for a meeting that runs late. Adapt the logistics to your own circumstances.

Choose one adjustment and see whether it solves the obstacle you identified. Did you have access to food when a break arrived? Was the refill arranged? Did the preparation task fit without displacing sleep?

If it did not work, note why. A missed break, nausea, and a forgotten lunch are different problems. Describe the practical barrier to your care team when you need help; there is no need to turn a difficult week into a judgment about your effort.

A useful routine is one you can revise as work and health needs change. Start with the next few days, keep medical decisions with your care team, and let the plan become more workable through experience.

General educational information only; not individualized medical advice.

Sources

1. FDA. Are You Storing Food Safely. Official food-storage guidance. Read source

2. Novo Nordisk. Wegovy Prescribing Information and Medication Guide. Revised June 2026. Injection instructions and patient safety warnings. Read source

3. Eli Lilly. Zepbound Medication Guide. Revised August 2026. Administration, storage, and safety warnings. Read source

4. CDC NIOSH. Coping with the Night and Evening Shifts Sleep. Reviewed March 31, 2020. General occupational guidance. Read source

5. CDC. Adding Physical Activity as an Adult. December 4, 2025. General adult activity guidance. Read source

6. FDA. Handling Food Safely While Eating Outdoors. Cooler and cold-food guidance. Read source

Related HCW reading

Meal planning for GLP 1 users

Low appetite and small meals

Strength training for beginners

Progress beyond the scale